Supernus Pharmaceuticals, Inc.
SUPN Nasdaq· Pharmaceutical Preparations
Last close · Oct 26, 2026
$40.77
KIRA · Stoqly’s AI analyst, in plain words
- Supernus Pharmaceuticals, Inc. had $719M of revenue in fiscal 2025, up 8.6% on the year before. Over five years, revenue changed +6.7% a year on average.
- Its operating margin was −8.7%, down 21.0 pts: of every 100 in sales, about −9 is left after running the business.
- Supernus Pharmaceuticals, Inc. lost $38.6M in fiscal 2025.
- Free cash flow was $46.0M in fiscal 2025, 6.4% of revenue.
Market cap
$2.4B
P/E
—
Revenue
$719M
Net income
−$38.6M
Free cash flow
$46.0M
Operating margin
−8.7%
Supernus Pharmaceuticals, Inc. in 30 seconds · fiscal 2025
Are sales growing?
+8.6%
Yes. Sales grew 8.6% last year.
Does it make a profit?
−5.4%
No. It lost money last year.
Does profit turn into cash?
6.4%
Partly. 6.4% of sales ends up as free cash.
How healthy are the accounts?
4 / 8
Mixed. It passes 4 of 8 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Supernus Pharmaceuticals, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 2, 2026
- Legal name
- SUPERNUS PHARMACEUTICALS, INC.
- CIK
- 0001356576
Supernus Pharmaceuticals, Inc. · SUPN
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $580M | $667M | $608M | $662M | $719M |
| Revenue growth | 11.4% | 15.1% | −8.9% | 8.9% | 8.6% |
| Gross margin | — | 86.9% | 86.2% | 88.2% | 89.6% |
| Operating margin | 14.8% | 6.9% | −0.9% | 12.3% | −8.7% |
| Net income | $53.4M | $60.7M | $1.3M | $73.9M | −$38.6M |
| Net margin | 9.2% | 9.1% | 0.2% | 11.2% | −5.4% |
| Diluted EPS | $0.98 | $1.04 | $0.02 | $1.32 | −$0.68 |
| Cash | |||||
| Cash from operations | $127M | $117M | $111M | $172M | $47.3M |
| Capital expenditure | — | $0.4M | $0.6M | $0.7M | $1.3M |
| Free cash flow | — | $116M | $111M | $171M | $46.0M |
| FCF margin | — | 17.4% | 18.2% | 25.9% | 6.4% |
| Share count change | 1.2% | 13.5% | −10.0% | 0.8% | 0.9% |
| Debt and strength | |||||
| Cash and short-term investments | $340M | $461M | $75.1M | $69.3M | $128M |
| Debt incl. finance leases | $379M | — | — | — | — |
| Shareholders' equity | $816M | $886M | $922M | $1.0B | $1.1B |
| Net debt / EBITDA | 0.3x | — | — | — | — |
| Current ratio | 1.9x | 1.1x | 1.7x | 2.3x | 1.9x |
| Interest coverage | 4.4x | 6.5x | −2.2x | — | — |
| Returns and quality | |||||
| Return on capital | 7.3% | — | — | — | — |
| Return on equity | 6.8% | 7.1% | 0.1% | 7.5% | −3.7% |
| Return on tangible equity | — | 96.3% | 0.6% | 18.6% | −10.5% |
| Piotroski F-score | 3 | 5 | 6 | 7 | 4 |
| Altman Z'' | 3.2 | 2.4 | 5.0 | 6.9 | 5.1 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$10.3M
7 insiders
Of sales under plans
82%
$8.4M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Supernus Pharmaceuticals, Inc. · SUPN
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $40.77 a share, the company is worth $2.4B.
Source: SEC EDGAR XBRL filings (CIK 0001356576). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.